Latest Conference Articles

October 1st 2022, 10:00am

Society of Hematologic Oncology Annual Meeting (SOHO)

Belantamab mafodotin plus lenalidomide and dexamethasone showed durable responses in patients with relapsed/refractory multiple myeloma.

September 30th 2022, 2:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Treatment with rusfertide generated sustained hematocrit control at levels below 45% in patients with polycythemia vera, leading to a reduced need for repeated phlebotomy and eliminating this need in some patients, according to findings from 2 phase 2 clinical trials.

September 29th 2022, 8:55pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Ivosidenib plus azacitidine displayed favorable event-free survival, overall survival, and clinical responses compared with placebo plus azacitidine in patients with newly diagnosed, IDH1-mutated acute myeloid leukemia, according to findings from the phase 3 AGILE study.

September 21st 2022, 6:45pm

ESMO Congress

Alpelisib decreased the need for surgery and led to improvements in performance status and disease-related signs and symptoms in pediatric patients with PIK3CA-related overgrowth spectrum disease who received treatment with the PI3K inhibitor under compassionate use.

September 13th 2022, 7:17pm

ESMO Congress

The decline of prostate-specific antigen following treatment with lutetium Lu 177 vipivotide tetraxetan plus standard of care was linked with prolonged radiographic progression-free survival and overall survival in patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

September 13th 2022, 12:28am

ESMO Congress

The combination of lenvatinib and pembrolizumab was found to induce high response rates, including long-lasting remissions, and have acceptable safety in patients with metastasized anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma.

September 12th 2022, 7:38pm

OncLive News Network: On Location at ESMO 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

September 12th 2022, 7:20pm

ESMO Congress: Hematologic Malignancies

GSK3326595, a PRMT5 inhibitor, displayed modest efficacy and safety signals that were consistent with those that were previously reported with the agent among patients with advanced solid tumors.

September 12th 2022, 7:19pm

ESMO Congress: GI Cancers

Adagrasib monotherapy and in combination with cetuximab generated encouraging responses in patients with advanced colorectal cancer harboring KRAS G12C mutations.

September 12th 2022, 7:16pm

ESMO Congress

Ribociclib plus endocrine therapy elicited statistically significant progression-free survival and overall survival benefits vs placebo plus endocrine therapy in patients with hormone receptor–positive/HER2-negative advanced breast cancer with visceral metastases, including those with liver metastases and multiple metastatic sites.

September 12th 2022, 6:30pm

ESMO Congress: Breast Cancer

An analysis of patient-reported outcomes from the phase 2 KEYNOTE-522 trial demonstrated that pembrolizumab was not associated with effects on health-related quality of life in patients with triple-negative breast cancer.

September 12th 2022, 5:53pm

ESMO Congress

Paul A. DiSilvestro, MD, discusses the 7-year follow up data of maintenance olaparib in advanced ovarian cancer.

September 12th 2022, 5:49pm

ESMO Congress

John H. Strickler, MD, discusses the results of tucatinib monotherapy in HER2-positive colorectal cancer.

September 12th 2022, 4:54pm

ESMO Congress: Hematologic Malignancies

Results from a retrospective analysis presented during the 2022 ESMO Congress indicated that circulating tumor DNA could potentially be leveraged as a prognostic factor and a tumor-specific biomarker for diffuse large B-cell lymphoma in China.

September 12th 2022, 4:50pm

ESMO Congress: Hematologic Malignancies

The combination of orelabrutinib and R-CHOP elicited a favorable overall response rate and progression-free response rate in patients with previously untreated non–germinal center B-cell–like diffuse large B-cell lymphoma (DLBCL) with extranodal disease.

September 12th 2022, 4:09pm

ESMO Congress: GU Cancers

The combination of pembrolizumab and olaparib did not significantly improve radiographic progression-free survival and overall survival compared with novel hormonal agents in patients with molecularly unselected, previously treated metastatic castration-resistant prostate cancer.

September 12th 2022, 4:03pm

ESMO Congress

The combination of enfortumab vedotin and pembrolizumab elicited a high overall response rate and a manageable safety profile in patients with locally advanced or metastatic urothelial cancer.

September 12th 2022, 3:20pm

ESMO Congress: GU Cancers

The addition of 24 months of androgen deprivation therapy to postoperative radiotherapy after radical prostatectomy provided a metastasis-free survival benefit and improved time to salvage therapy in patients with prostate cancer.

September 12th 2022, 2:42pm

ESMO Congress

Tucatinib plus trastuzumab improved radiographic response rates in patients with metastatic HER2-positive colorectal cancer initially treated with tucatinib monotherapy who later crossed over to receive doublet therapy.

September 12th 2022, 2:40pm

ESMO Congress: Lung Cancer

The clinical benefit and tolerable safety profile of trastuzumab deruxtecan was maintained at 5.4 kg/mg vs 6.4 kg/mg in patients with HER2-mutated non–small cell lung cancer, confirming the benefit-risk ratio of the FDA-approved dose.